Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Colorectal Adenocarcinoma, Not Just One Disease.

Stachler MD.

Cell Mol Gastroenterol Hepatol. 2019;8(2):293-294. doi: 10.1016/j.jcmgh.2019.04.012. Epub 2019 May 23. No abstract available.

2.

Clinicopathologic and genetic characteristics of interval colorectal carcinomas favor origin from missed or incompletely excised precursors.

Soong TR, Nayor J, Stachler MD, Perencevich M, Jajoo K, Saltzman JR, Lindeman NI, Srivastava A.

Mod Pathol. 2019 May;32(5):666-674. doi: 10.1038/s41379-018-0176-6. Epub 2018 Nov 19.

PMID:
30455417
3.

Biomarkers for Barrett's esophagus - a contemporary review.

Qureshi AP, Stachler MD, Haque O, Odze RD.

Expert Rev Mol Diagn. 2018 Nov;18(11):939-946. doi: 10.1080/14737159.2018.1538793. Epub 2018 Nov 1. Review.

PMID:
30345836
4.

Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.

Stachler MD, Camarda ND, Deitrick C, Kim A, Agoston AT, Odze RD, Hornick JL, Nag A, Thorner AR, Ducar M, Noffsinger A, Lash RH, Redston M, Carter SL, Davison JM, Bass AJ.

Gastroenterology. 2018 Jul;155(1):156-167. doi: 10.1053/j.gastro.2018.03.047. Epub 2018 Mar 31.

5.

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV.

Cancer Discov. 2018 Jan;8(1):37-48. doi: 10.1158/2159-8290.CD-17-0395. Epub 2017 Oct 4.

6.

Paired exome analysis of Barrett's esophagus and adenocarcinoma.

Stachler MD, Taylor-Weiner A, Peng S, McKenna A, Agoston AT, Odze RD, Davison JM, Nason KS, Loda M, Leshchiner I, Stewart C, Stojanov P, Seepo S, Lawrence MS, Ferrer-Torres D, Lin J, Chang AC, Gabriel SB, Lander ES, Beer DG, Getz G, Carter SL, Bass AJ.

Nat Genet. 2015 Sep;47(9):1047-55. doi: 10.1038/ng.3343. Epub 2015 Jul 20.

7.

Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.

Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, Sicinska E, Goldberg MS, Freeman GJ, Rodig SJ, Davison JM, Bass AJ.

Cancer Immunol Res. 2015 Oct;3(10):1123-1129. doi: 10.1158/2326-6066.CIR-15-0046. Epub 2015 Jun 16.

8.

PIK3CA Mutations are Common in Many Tumor Types and are Often Associated With Other Driver Mutations.

Stachler MD, Rinehart EM, Garcia E, Lindeman NI.

Appl Immunohistochem Mol Morphol. 2016 May-Jun;24(5):313-9. doi: 10.1097/PAI.0000000000000195.

PMID:
26067136
9.

Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.

Kaz AM, Grady WM, Stachler MD, Bass AJ.

Gastroenterol Clin North Am. 2015 Jun;44(2):473-89. doi: 10.1016/j.gtc.2015.02.015. Epub 2015 Apr 1. Review.

10.

Novel molecular insights from routine genotyping of colorectal carcinomas.

Stachler MD, Rinehart E, Lindeman N, Odze R, Srivastava A.

Hum Pathol. 2015 Apr;46(4):507-13. doi: 10.1016/j.humpath.2015.01.005. Epub 2015 Jan 14.

PMID:
25683705
11.

Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.

Hong YS, Kim J, Pectasides E, Fox C, Hong SW, Ma Q, Wong GS, Peng S, Stachler MD, Thorner AR, Van Hummelen P, Bass AJ.

PLoS One. 2014 Oct 28;9(10):e109440. doi: 10.1371/journal.pone.0109440. eCollection 2014.

12.

Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.

Baden LR, Liu J, Li H, Johnson JA, Walsh SR, Kleinjan JA, Engelson BA, Peter L, Abbink P, Milner DA Jr, Golden KL, Viani KL, Stachler MD, Chen BJ, Pau MG, Weijtens M, Carey BR, Miller CA, Swann EM, Wolff M, Loblein H, Seaman MS, Dolin R, Barouch DH.

J Infect Dis. 2015 Feb 15;211(4):518-28. doi: 10.1093/infdis/jiu485. Epub 2014 Aug 26.

13.

Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer.

Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, Zlobec I, Karamitopoulou E, Stachler MD, Odze RD, Lencer WI, Jobin C, Blumberg RS.

Immunity. 2013 Dec 12;39(6):1095-107. doi: 10.1016/j.immuni.2013.11.003. Epub 2013 Nov 27.

14.

Single molecule tracking of P-glycoprotein in live cells reveals dynamic heterogeneity.

Cheney PP, Stachler MD, Knowles MK.

Conf Proc IEEE Eng Med Biol Soc. 2012;2012:3159-62. doi: 10.1109/EMBC.2012.6346635.

PMID:
23366596
15.

Case report: Calcifying fibrous tumor presenting as an asymptomatic pelvic mass.

Giardino AA, Ramaiya NH, Shinagare AB, Jagannathan JP, Stachler MD, Raut CP.

Indian J Radiol Imaging. 2011 Oct;21(4):306-8. doi: 10.4103/0971-3026.90700.

16.

Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase.

Stachler MD, Chen I, Ting AY, Bartlett JS.

Mol Ther. 2008 Aug;16(8):1467-73. doi: 10.1038/mt.2008.129. Epub 2008 Jun 17.

17.

Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes.

Arnold GS, Sasser AK, Stachler MD, Bartlett JS.

Mol Ther. 2006 Jul;14(1):97-106. Epub 2006 Apr 19.

Supplemental Content

Loading ...
Support Center